Key result
CRT-D linked to ~30% lower 1-year mortality vs. DC-ICD in patients requiring ventricular pacing.
Why the study?
Although CRT is associated with improved outcomes in patients with reduced LVEF requiring frequent RV pacing, clinical practice patterns and outcomes of CRT versus dual-chamber ICDs among patients without a class I CRT indication were unknown.
Does implantation of a cardiac resynchronization therapy defibrillator (CRT-D) reduce 1-year all-cause mortality and heart failure hospitalization compared with a dual chamber ICD (DC-ICD) in older patients undergoing ICD implantation with a bradycardia pacing indication but without a class I indication for CRT?
Cohort (n=3,100)
Yes
Does implantation of a cardiac resynchronization therapy defibrillator (CRT-D) reduce 1-year all-cause mortality and heart failure hospitalization compared with a dual chamber ICD (DC-ICD) in older patients undergoing ICD implantation with a bradycardia pacing indication but without a class I indication for CRT?
In real-world older patients requiring an ICD and ventricular bradycardia pacing without a class I CRT indication, CRT-D implantation was associated with significantly lower 1-year mortality and heart failure hospitalization without increased procedural complications compared with DC-ICD.
Answers are grounded in this paper and cite their sources.
May inform CRT-D selection in older patients needing ventricular pacing; leaves open randomized confirmation of benefit.
Importance: Frequent right ventricular (RV) pacing can cause and exacerbate heart failure. Cardiac resynchronization therapy (CRT) has been shown to be associated with improved outcomes among patients with reduced left ventricular ejection fraction who need frequent RV pacing, but the patterns of use of CRT vs dual chamber (DC) devices and the associated outcomes among these patients in clinical practice is not known. Objective: To assess outcomes, variability in use of device type, and trends in use of device type over time among patients undergoing implantable cardioverter defibrillator (ICD) implantation who were likely to require frequent RV pacing but who did not have a class I indication for CRT. Design, Setting, and Participants: This retrospective cohort study used the National Cardiovascular Data Registry (NCDR) ICD Registry. A total of 3100 Medicare beneficiaries undergoing first-time implantation of CRT defibrillator (CRT-D) or DC-ICD from 2010 to 2016 who had a class I or II guideline ventricular bradycardia pacing indication but not a class I indication for CRT were included. Data were analyzed from August 2018 to October 2019. Exposures: Implantation of a CRT-D or DC-ICD. Main Outcomes and Measures: All-cause mortality, heart failure hospitalization, and complications were ascertained from Medicare claims data. Multivariable Cox proportional hazards models and Fine-Gray models were used to evaluate 1-year mortality and heart failure hospitalization, respectively. Multivariable logistic regression was used to evaluate 30-day and 90-day complications. All models accounted for clustering. The median odds ratio (MOR) was used to assess variability and represents the odds that a randomly selected patient receiving CRT-D at a hospital with high implant rates would receive CRT-D if they had been treated at a hospital with low CRT-D implant rates. Results: A total of 3100 individuals were included. The mean (SD) age was 76.3 (6.4) years, and 2500 (80.6%) were men. The 1698 patients (54.7%) receiving CRT-D were more likely than those receiving DC-ICD to have third-degree atrioventricular block (828 [48.8%] vs 432 [30.8%]; P < .001), nonischemic cardiomyopathy (508 [29.9%] vs 255 [18.2%]; P < .001), and prior heart failure hospitalizations (703 [41.4%] vs 421 [30.0%]; P < .001). Following adjustment, CRT-D was associated with lower 1-year mortality (hazard ratio [HR], 0.70; 95% CI, 0.57-0.87; P = .001) and heart failure hospitalization (subdistribution HR, 0.77; 95% CI, 0.61-0.97; P = .02) and no difference in complications compared with DC-ICD. Hospital variation in use of CRT was present (MOR, 2.00), and the use of CRT in this cohort was higher over time (654 of 1351 [48.4%] in 2010 vs 362 of 594 [60.9%] in 2016; P < .001). Conclusions and Relevance: In this cohort study of older patients in contemporary practice undergoing ICD implantation with a bradycardia pacing indication but without a class I indication for CRT, CRT-D was associated with better outcomes compared with DC devices. Variability in use of device type was observed, and the rate of CRT implantation increased over time.
No takes yet. Share an insight, caveat, or question.
Borne et al. (2021) conducted a cohort in Ventricular bradycardia pacing indication undergoing first-time ICD implantation without a class I CRT indication (n=3,100). Cardiac resynchronization therapy defibrillator (CRT-D) implantation vs. Dual chamber implantable cardioverter defibrillator (DC-ICD) implantation was evaluated on 1-year all-cause mortality (HR 0.70, 95% CI 0.57-0.87, p=0.001). CRT-D implantation was associated with lower 1-year all-cause mortality compared with DC-ICD in older patients requiring ventricular pacing.
Synapse has enriched 10 related papers. Consider them for comparative context: